Responsiveness of the national eye institute visual function questionnaire-25 to visual acuity gains in patients with diabetic macular edema: Evidence from the RIDE and RISE Trials

Ivan J. Suñer, Neil M. Bressler, Rohit Varma, Chantal M. Dolan, James Ward, Adam Turpcu

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To evaluate the responsiveness of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in patients with diabetic macular edema using data from the RIDE and RISE trials. Methods: Patients were randomized to monthly intravitreal ranibizumab 0.3 mg, 0.5 mg, or sham injections for 2 years. The NEI VFQ-25 was administered at baseline and at Months 6, 12, 18, and 24. The least-squares mean change in NEI VFQ-25 for ≥15 letters gained or lost was derived from analysis of covariance models. Results: The mean improvement in NEI VFQ-25 composite score associated with a ≥15-letter gain in best-corrected visual acuity over 24 months was 9.0 (95% confidence interval, 6.3-11.7) points in RIDE and 7.1 (95% confidence interval, 4.7-9.6) points in RISE. In patients who lost ≥15 letters, the mean worsening in overall NEI VFQ-25 composite score was -6.6 (95% confidence interval, -13.6 to 0.5) in RIDE and -2.7 (95% confidence interval, -8.9 to 3.5) in RISE. Conclusion: This exploratory analysis of data from the RIDE and RISE studies supports the responsiveness of the NEI VFQ-25 to changes in best-corrected visual acuity over time in patients with diabetic macular edema.

Original languageEnglish (US)
Pages (from-to)1126-1133
Number of pages8
JournalRetina
Volume37
Issue number6
DOIs
StatePublished - Jun 1 2017

Keywords

  • National Eye Institute Visual Function Questionnaire-25
  • diabetic macular edema
  • visual acuity

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Responsiveness of the national eye institute visual function questionnaire-25 to visual acuity gains in patients with diabetic macular edema: Evidence from the RIDE and RISE Trials'. Together they form a unique fingerprint.

Cite this